Form 4: Phio Pharmaceuticals CEO Robert Bitterman Buys 1,500 Shares in Open Market

Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, acquired 1,500 shares of common stock at $2.75 per share, increasing his beneficial ownership to 25,149 shares.

Summary

• Robert J. Bitterman, who serves as Director, Chairman, President, and CEO of Phio Pharmaceuticals Corp. (PHIO), purchased 1,500 shares of the company's common stock.
• The transaction occurred on June 9, 2025, at a price of $2.75 per share.
• Following this acquisition, Mr. Bitterman beneficially owns a total of 25,149 shares of Phio Pharmaceuticals Corp. common stock.
• The reported beneficial ownership includes shares of common stock underlying unvested restricted stock units.
• The transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The insider purchase by the CEO is generally viewed as a positive signal, indicating management's confidence in the company's valuation and future prospects.

Positives

• The purchase of shares by the Chairman, President, and CEO, Robert J. Bitterman, signals management's confidence in the company's future prospects and current valuation.
• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-planned acquisition strategy.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is an insider trading report (Form 4) and does not provide broader industry context or trends. It focuses solely on a specific transaction by a company insider.

Related Party Transactions

• The acquisition of 1,500 shares of common stock by Robert J. Bitterman, the Chairman, President, and CEO, constitutes a related party transaction as it involves a company insider purchasing securities from the issuer.

Stakeholder Impact

• Shareholders may interpret the insider purchase as a positive indicator of management's belief in the company's value, potentially influencing investor sentiment and stock price.

Key Dates

Keywords

Phio Pharmaceuticals, PHIO, Insider Trading, Form 4, Stock Purchase, Robert J. Bitterman, CEO, Director, Common Stock, Rule 10b5-1